Avience Biomedicals IPO: Strong Debut Expected as GMP Hits 62% Premium

Avience Biomedicals is poised for a blockbuster entry onto the NSE SME platform this Thursday, backed by massive investor enthusiasm. With grey market signals suggesting a significant markup, market participants are bracing for a high-impact listing.

Massive Subscription Numbers Drive Investor Frenzy

The ₹30.24 crore initial public offering (IPO) has seen unprecedented demand, reflecting deep confidence in the company's growth trajectory. The issue, which consists entirely of a fresh issue of 14.54 lakh shares, was subscribed a staggering 385.32 times during its three-day bidding window.

The demand was particularly aggressive in the Non-Institutional Investor (NII) segment, which saw a subscription of 597.23 times. Retail investors also showed intense interest, subscribing to 401.36 times the available portion. Meanwhile, Qualified Institutional Buyers (QIBs) contributed to the momentum with a 196.77 times subscription. This overwhelming response underscores the high liquidity and interest currently present in the SME IPO segment.

Grey Market Signals a High Listing Premium

Current grey market activity suggests that Avience Biomedicals could list well above its issue price of ₹208 per share. As of the latest reports, the stock is commanding a Grey Market Premium (GMP) of approximately 62%.

If these unofficial signals hold true, investors could see an estimated listing price of around ₹337 per share. While GMP serves as a vital sentiment indicator for traders, it remains an unofficial metric and does not guarantee the final listing price, which will ultimately depend on market volatility and listing day demand.

Business Model and Expansion Plans

Incorporated in 2024, Avience Biomedicals has quickly positioned itself as a key player in the molecular diagnostic solutions sector. The company caters to high-growth industries, including biotechnology, genomics, and in-vitro diagnostics (IVD). Their diverse product portfolio spans rapid test kits, biochemistry and hematology analysers, reagents, and various medical devices.

The company serves a broad client base, including pathology laboratories, hospitals, research centers, and government institutions both in India and internationally. A significant portion of the IPO proceeds is earmarked for capital expenditure, specifically to fund a new manufacturing facility at the Medical Device Park under the Yamuna Expressway Industrial Development Authority in Uttar Pradesh. This expansion is intended to bolster their production capacity and meet increasing working capital requirements.

Robust Financial Performance

The company's financial health appears strong as it enters the public markets. For FY25, Avience Biomedicals reported a total income of ₹45.97 crore with a net profit of ₹7.23 crore. The momentum has continued into the current fiscal year, with the company posting a revenue of ₹41.94 crore and a profit after tax (PAT) of ₹5.74 crore for the nine months ended January 2026.

Key Takeaways

  • High Demand: The IPO was oversubscribed 385.32 times, led by massive interest from NII (597.23x) and retail (401.36x) investors.
  • Strong Premium: Grey market signals indicate a potential 62% premium, suggesting a listing price near ₹337 against the ₹208 issue price.
  • Strategic Growth: Proceeds will fund a new manufacturing unit in Uttar Pradesh to expand their molecular diagnostic and medical device footprint.